Categories: EHRNewsPharmaceutical

Compass Therapeutics to Participate in Upcoming May Investor Events

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May.

Details are as follows:

The Citizens Life Sciences Conference
Location: New York, NY
Date: Thursday, May 8, 2025
Time: 1:30 PM ET
Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592

H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Location: New York, NY
Date: Tuesday, May 20, 2025
Time: 11:30AM ET
Webcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3560aa9a1

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099

Staff

Recent Posts

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

50 minutes ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

50 minutes ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

50 minutes ago

Shrub Oak International School Reinforces Unwavering Commitment to Student Safety and Security

MOHEGAN LAKE, N.Y., Dec. 5, 2025 /PRNewswire/ -- Shrub Oak International School today announced enhanced…

50 minutes ago

‘I’D RATHER GET A ROOT CANAL’: US WORKERS DREAD THE OFFICE HOLIDAY PARTY

National poll reveals 27% of workers prefer dental work over office celebrations as workplace disconnection…

50 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA…

51 minutes ago